HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Repertaxin, an inhibitor of the chemokine receptors CXCR1 and CXCR2, inhibits malignant behavior of human gastric cancer MKN45 cells in vitro and in vivo and enhances efficacy of 5-fluorouracil.

Abstract
Chemokine-mediated activation of G protein-coupled receptors CXCR1/2 promotes tumor growth, invasion, inflammation and metastasis. Repertaxin, a CXCR1/2 small-molecule inhibitor, has been shown to attenuate many of these tumor-associated processes. The present study aimed to investigate the effects of repertaxin alone and in combination with 5-fluorouracil (5-FU) on the malignant behavior of gastric cancer and the potential mechanisms. Gastric cancer MKN45 cells were treated in vitro with repertaxin and 5-FU, either alone or in combination. MTT and colony formation assay were performed to assess proliferation. Cell cycle progression and apoptosis was completed by flow cytometry. Migration and invasion were also assessed by transwell and wound-healing assay. Western blot analysis and quantitative RT-PCR were performed to determine expression of signaling molecules. MKN45 cells were also grown as xenografts in nude mice. Mice were treated with repertaxin and 5-FU, and tumor volume and weight, angiogenesis, proliferation and apoptosis were monitored. Combination of repertaxin and 5-FU inhibited MKN45 cell proliferation and increased apoptosis better than either agent alone. Similarly, enhanced effect of the combination was also observed in migration and invasion assays. The improved effect of repertaxin and 5-FU was also observed in vivo, as xenograft models treated with both compounds exhibited significantly decreased tumor volume and increased apoptosis. In conclusion, repertaxin inhibited malignant behavior of human gastric cancer MKN45 cells in vitro and in vivo and enhances efficacy of 5-fluorouracil. These data provide rationale that targeting CXCR1/2 with small molecule inhibitors may enhance chemotherapeutic efficacy for the treatment of gastric cancer.
AuthorsJunpu Wang, Wanming Hu, Kuansong Wang, Jun Yu, Baihua Luo, Gengqiu Luo, Weiyuan Wang, Huiling Wang, Jinghe Li, Jifang Wen
JournalInternational journal of oncology (Int J Oncol) Vol. 48 Issue 4 Pg. 1341-52 (Apr 2016) ISSN: 1791-2423 [Electronic] Greece
PMID26847910 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Receptors, Interleukin-8A
  • Receptors, Interleukin-8B
  • Sulfonamides
  • Cisplatin
  • Fluorouracil
  • reparixin
Topics
  • Animals
  • Apoptosis (drug effects)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Cisplatin (administration & dosage)
  • Drug Resistance, Neoplasm
  • Fluorouracil (administration & dosage)
  • Gene Expression Regulation, Neoplastic (drug effects)
  • Humans
  • Mice
  • Receptors, Interleukin-8A (antagonists & inhibitors, biosynthesis)
  • Receptors, Interleukin-8B (antagonists & inhibitors, biosynthesis)
  • Signal Transduction (drug effects)
  • Stomach Neoplasms (drug therapy, genetics, pathology)
  • Sulfonamides (administration & dosage)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: